Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obitazidine Fumarate Enteric-coated Pellet Capsules (SM-1) in Combination With Temozolomide in Subjects With Refractory or Recurrent Gliomas: Phase I Trial

NCT07635173 is registered in ClinicalTrials.gov with Shenzhen Zhenxing Medical Technology Co., Ltd as lead sponsor.

NCT NCT07635173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07635173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obitazidine Fumarate Enteric-coated Pellet Capsules (SM-1) in Combination With Temozolomide in Subjects With Refractory or Recurrent Gliomas: Phase I Trial
Lead sponsor
Shenzhen Zhenxing Medical Technology Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
September 19, 2022
Completion date
March 28, 2026
Enrollment
35 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastomas (gbm), glioma, high grade gliomas